10-Q: Beyond Air Reports Second Quarter Fiscal 2025 Results, Secures New Financing

Beyond Air's Q2 2025 results show increased revenue but continued losses, alongside securing new financing and restructuring debt.

Summary

• Beyond Air reported a net loss of $14.0 million for the three months ended September 30, 2024, and $27.1 million for the six months ended September 30, 2024.
• Revenue for the quarter was $0.8 million, and $1.5 million for the six months, primarily from LungFit PH leases.
• The company's operating expenses were $11.7 million for the quarter and $25.0 million for the six months.
• A significant portion of the operating expenses was attributed to research and development and selling, general, and administrative costs.
• The company extinguished its senior secured term loan with Avenue Capital for a one-time payment of $17.85 million.
• Beyond Air secured a new $11.5 million loan with a 15% interest rate, payable in kind through July 2026, and an 8% royalty on net sales from July 2026.
• The company also completed a private placement offering, raising $18.9 million in net proceeds.
• As of September 30, 2024, Beyond Air had $28.7 million in cash, cash equivalents, and restricted cash.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While the company has secured new financing and is seeing revenue growth, it continues to experience significant losses and faces substantial risks. The sentiment is cautiously negative due to the ongoing financial challenges and the need for further capital.

Positives

• Revenue is increasing as the company continues to sign hospital contracts for LungFit PH.
• The new loan and private placement provide significant capital to support operations.
• Extinguishing the Avenue Capital loan eliminates a substantial amount of future debt and interest payments.
• The company has implemented a capital conservation strategy, reducing back office footprint and staffing levels.
• The company has signed agreements with TrillaMed, Healthcare Links, and Business Asia Consultants to drive increased revenues.

Negatives

• The company continues to experience significant net losses, with a $14.0 million loss for the quarter and $27.1 million for the six months.
• Cost of revenue exceeded revenue due to one-time costs for device upgrades, provisions for excess inventory, and depreciation.
• The company's operating expenses remain high, primarily due to research and development and selling, general, and administrative costs.
• The company has a history of accumulated losses, totaling $265.3 million.
• The company is dependent on third-party suppliers for materials, with two vendors accounting for a large portion of purchases.

Risks

• The company's ability to meet its obligations with current cash on hand is uncertain.
• The company's future capital needs depend on the success of commercialization and regulatory approvals.
• The company is subject to risks common to development and early-stage medical device companies.
• The company's products require regulatory approval, and there is no assurance of receiving such approvals.
• The company is dependent on third-party suppliers and, in some cases, single-source suppliers.
• The company may not be able to maintain its listing on the Nasdaq Capital Market.

Future Outlook

The company anticipates entering the final phase of its commercial launch in calendar 2025, aiming to become a market leader in the U.S. in a few years. The company expects to progress its nNOS program to a phase 1 clinical trial by the end of 2025. The company anticipates commencing a pivotal clinical trial for NTM in calendar year 2026 following discussions with the FDA.

Management Comments

• Management believes that efforts to increase revenues and decrease expenditures will enable the company to meet its obligations.
• Management is confident that the efforts it has implemented to increase revenues and decrease expenditures, while not assured, will enable the Company to meet its obligations.

Industry Context

The company operates in the medical device and biopharmaceutical industry, focusing on nitric oxide therapies. The market for nitric oxide treatments is substantial, with Mallinckrodt reporting $303.2 million in sales in 2023. The company is targeting various indications, including PPHN, viral pneumonia, bronchiolitis, and NTM, each with significant market potential. The company is also developing ultra-high concentration nitric oxide therapies for solid tumors through its affiliate, Beyond Cancer.

Comparison to Industry Standards

• Mallinckrodt Pharmaceuticals, a major player in the nitric oxide market, reported $303.2 million in sales in 2023, primarily in the U.S., Canada, Japan, Mexico and Australia, with >90% in the United States. This provides a benchmark for the potential market size for Beyond Air's LungFit PH.
• The company's focus on high-concentration nitric oxide for viral pneumonia and NTM infections differentiates it from current standard treatments, which typically use lower concentrations for vasodilation.
• The company's development of ultra-high concentration nitric oxide for solid tumors is a novel approach, with limited direct comparables in the market.
• The company's clinical trial results for bronchiolitis and NTM show promising trends in reducing hospital length of stay and improving patient outcomes, which are key metrics for evaluating the effectiveness of new therapies.

Related Party Transactions

• Certain directors and officers of the company participated in the private placement offering.
• The new loan agreement includes the company's Chief Executive Officer and a director as lenders.

Stakeholder Impact

• Shareholders are impacted by the company's continued losses and the potential for dilution from new equity issuances.
• Employees are impacted by the company's capital conservation strategy, including staffing reductions.
• Customers (hospitals) are impacted by the company's ability to supply and support LungFit PH devices.
• Creditors are impacted by the company's debt restructuring and new loan agreements.
• Suppliers are impacted by the company's reliance on a few key vendors.

Next Steps

• The company will continue to commercialize LungFit PH in the U.S. and work towards a potential launch in the EU and globally.
• The company will continue to develop its LungFit PRO system for viral lung infections and bronchiolitis.
• The company will continue to develop its LungFit GO system for NTM lung infections.
• The company will continue to advance its ultra-high concentration nitric oxide program for solid tumors through Beyond Cancer.
• The company will progress its nNOS program for neurological conditions.
• The company will seek shareholder approval to increase the number of authorized shares of common stock to allow for the exercise of warrants.

Key Dates

Keywords

LungFit PH, nitric oxide, PPHN, VCAP, bronchiolitis, NTM, UNO, Beyond Cancer, financing, medical device, clinical trials, revenue, net loss, warrants, loan